IFN-γ, SCF, MIP1b and IL-16 Were Associated with Risk of Diabetic Nephropathy: A Mendelian Randomization Study

Li An1,2, Xiaomei Ren1, Ye Pan2

  • 1Department of Geriatrics, ZhongDa Hospital, Southeast University School of Medicine, Nanjing, 210009, People's Republic of China.

Abstract

Insights

Certain inflammatory factors causally impact diabetic nephropathy (DN) risk. Interferon-gamma and SCF increase DN risk, while MIP1b and IL-16 decrease it, offering therapeutic targets.

Area of Science:

  • Genetics
  • Immunology
  • Nephrology

Background:

  • The relationship between inflammatory factors and diabetic nephropathy (DN) risk is not fully understood.
  • Existing research presents inconsistent findings regarding the impact of inflammation on DN development.

Purpose of the Study:

  • To investigate the causal role of various inflammatory factors in the risk of developing diabetic nephropathy (DN).
  • To leverage Mendelian randomization (MR) to analyze genetic data and infer causality.

Main Methods:

  • Two-sample Mendelian randomization (MR) analyses were employed using large-scale genome-wide association study (GWAS) data.
  • Data included inflammatory factor GWAS summary statistics from 8,293 Finnish participants and DN GWAS data from 213,746 FinnGen individuals.
  • MR Pleiotropy Residual Sum and Outlier (MR-PRESSO) and multivariable MR analyses were used to address potential pleiotropy and validate findings.

Main Results:

  • Interferon-gamma (IFN-γ) and Stem Cell Factor (SCF) were significantly associated with an increased risk of DN.
  • Macrophage Inflammatory Protein-1 beta (MIP1b) and Interleukin-16 (IL-16) showed a significant negative association with DN risk.
  • MR-PRESSO and multivariable MR analyses confirmed these associations and found no significant horizontal pleiotropy.

Conclusions:

  • Genetic evidence supports a causal role for specific inflammatory factors in the pathogenesis of diabetic nephropathy (DN).
  • Targeting identified inflammatory factors may offer a novel therapeutic strategy to mitigate DN risk.